About Us

About CereXis.

CereXis is a clinical-stage biopharmaceutical company focused on bringing effective therapies targeted at rare cancers to patients. The most advanced clinical program at CereXis is for patients with Neurofibromatosis type 2, an autosomal dominant syndrome characterized by multiple tumors of the nervous system, especially in the brain and spinal cord.

Cerexis lead program, REC-2282 is in clinical development for the treatment of patients with Neurofibromatosis type 2 (NF2), an autosomal dominant syndrome characterized by multiple recurrent tumors of the nervous system that are associated with significant morbidities and mortality. NF2 is most commonly associated with bilateral vestibular schwannomas, also known as acoustic neuromas. These are benign (non-cancerous) tumors that occur on the nerves responsible for balance and hearing in the inner ear. Patients may also develop meningiomas, slow-growing tumors that usually emerge on the surface of the brain and in severe cases can be life threatening.

Primary Asset: REC-2282

Our lead drug candidate, REC-2282 (also known as AR-42), is an orally administered, brain-penetrant histone deacetylase (HDAC) inhibitor.

1. Target Condition: It is designed to treat patients with Neurofibromatosis Type 2 (NF2), a rare genetic disorder characterized by the growth of multiple noncancerous tumors in the nervous system, such as meningiomas and schwannomas.

2. Mechanism: REC-2282 works by affecting gene regulation to slow or stop the growth of tumors associated with NF2 mutations